“Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer” detailed CHCWM’s Cardiff Oncology study, which is currently open. Manish Sharma, MD, is credited as the first author. For more information on this clinical trial and its presentation, click here.
“Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors” detailed START Midwest’s Bolt Biotherapeutics study, which is currently open as well. Dr. Sharma is also credited as the first author. For more information on this clinical trial and its presentation, click here.
Founded in 1979, CHCWM has grown to become the largest physician-owned oncology and hematology practice in Michigan. We deliver advanced care in a personal way, and our expertise and caring approach make us dedicated to the help, healing and hope for cancer patients and their families. Thanks to the hard work of our growing staff, CHCWM has been named one of the Nation’s Best and Brightest Companies to Work For®. To learn more about CHCWM, visit chcwm.com.
START Midwest, located at CHCWM’s East site, is part of START’s global network of Phase I clinical research sites. It is the largest Phase I oncology drug development program in Michigan and one of the largest in the Midwest. It offers cancer patients access to cutting-edge clinical trial drugs, including immunotherapy and targeted therapy options.
Becky Downing, Social Media & Marketing Specialist